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Abstract: Equine influenza virus (EIV) is a constantly evolving viral pathogen that is responsible for
yearly outbreaks of respiratory disease in horses termed equine influenza (EI). There is currently
no evidence of circulation of the original H7N7 strain of EIV worldwide; however, the EIV H3N8
strain, which was first isolated in the early 1960s, remains a major threat to most of the world’s
horse populations. It can also infect dogs. The ability of EIV to constantly accumulate mutations
in its antibody-binding sites enables it to evade host protective immunity, making it a successful
viral pathogen. Clinical and virological protection against EIV is achieved by stimulation of strong
cellular and humoral immunity in vaccinated horses. However, despite EI vaccine updates over the
years, EIV remains relevant, because the protective effects of vaccines decay and permit subclinical
infections that facilitate transmission into susceptible populations. In this review, we describe
how the evolution of EIV drives repeated EI outbreaks even in horse populations with supposedly
high vaccination coverage. Next, we discuss the approaches employed to develop efficacious EI
vaccines for commercial use and the existing system for recommendations on updating vaccines
based on available clinical and virological data to improve protective immunity in vaccinated horse
populations. Understanding how EIV biology can be better harnessed to improve EI vaccines is
central to controlling EI.
Keywords: equine influenza; equine influenza virus; equine influenza vaccine; H3N8; adaptive
immunity; cellular immunity; humoral immunity; surveillance; experimental infection
1. Recent Outbreaks of EIV
The transboundary transport of horses has allowed infectious disease pathogens
to cross geographical barriers between nations of the world [1,2], enabling their spread
to disease-free countries (Figure 1). During horse events such as horse races and shows,
horses from different parts of the world congregate and are sometimes held at high stocking
density, enabling close contacts and predisposal to EIV. The importation of subclinically
infected carrier horses and poor biosecurity/quarantine measures can facilitate the spread
of EIV to naïve horse populations, leading to major outbreaks.
1986–1999: EIV was long recognized as an important equine respiratory pathogen
in Europe and North America, but three outbreaks near the end of the 1980s brought it
into new prominence. First, a 1986 outbreak in South Africa [3], where H3N8 EIV had
previously been unknown and occurring at just the time that nucleotide sequencing was
becoming commonplace, triggered the first important genetic evolutionary studies of the
EIV H3 hemagglutinin (HA) [4,5] and implicated newly imported horses. In 1989 occurred
the large European outbreak associated with Suffolk/89 virus [6], as well as a large-scale
outbreak in China of H3N8 avian influenza in horses [7] that, fortunately, did not persist.
An outbreak in Hong Kong in 1992 [8] was intensively investigated and provided the first
indication of the bifurcation of the American and Eurasian lineages.
Viruses 2021, 13, 1657. https://doi.org/10.3390/v13081657 https://www.mdpi.com/journal/viruses
Viruses 2021, 13, 1657 2 of 36
2000–2010: South Africa, which had eradicated EIV by 1987, suffered its second
EIV outbreak in 2003, again from imported horses, which yielded the prototype Florida
clade 1 (FC-1) strain, influenza A/equine/South Africa/2003 [9]. Australia, which had
historically been free from EIV, endured a huge outbreak of FC-1 EIV in 2007, affecting
70,000 horses [10]. The source was imported horses that had been vaccinated but were still
subclinically infected, and the virus somehow escaped from the postimport quarantine
facility into the domestic population, which had never been vaccinated. This outbreak
was eradicated within six months, and Australia returned to EIV-free status due to a
combination of stringent horse (movement restrictions and a policy of targeted and ring)
vaccination using exclusively vaccines that allow distinguishing between infected and
vaccinated animals (differentiation of infected from vaccinated animals (DIVA)-capable
vaccines) [11].
2010–2021: Over the last decade, multiple outbreaks of EIV infection were reported
in many countries from different continents around the world (Table 1 and Figure 2).
Increased outbreaks of EIV were reported not only in North America [12], especially in the
United States (US) where the disease is endemic, but also in Europe [13–15], Africa [16–18],
Asia [12,19,20], and South America [21–26]. Recently, in the US, outbreaks were reported
in 23 states in 2015, 16 states in 2016, 22 states in 2017, and 33 states between the end
of 2018 and the first third of 2019 [12,27]. EIV is not a notifiable disease in the US, so
under-reporting is likely. In Europe, outbreaks have been reported over the years in France,
Germany, Ireland, Sweden, and the United Kingdom (UK) [12]. The most recent outbreak
of EIV across Europe was quite extensive, affecting 228 horse premises in the UK, 80 in
Ireland, and 60 in France from the end of 2018 to 2019 according to the World Organization
for Animal Health (OIE) report [27]. These outbreaks occurred among both vaccinated and
unvaccinated horses, with reduced clinical manifestation observed in vaccinated horses,
especially those with a history of appropriate and up-to-date vaccination over several years.
This highlights the importance of maintaining homogeneity between vaccine strains and
the circulating EIV strains to induce a long-lasting immunity in vaccinated horses. The
observation of disease in vaccinated horses may also indicate a possible vaccine breakdown
necessitating vaccine verification and appropriate use or administration to forestall future
outbreaks. Outbreaks of EIV are uncommonly reported in Africa, but recently, beginning
from November of 2018 to 2019, outbreaks were reported in many African countries
affecting horses and donkeys [16,17,27]. This unusual epizootic outbreak was responsible
for the mortality of over 66,000 horses and donkeys across Burkina Faso, Chad, Cameroon,
The Gambia, Ghana, Mali, Niger, Nigeria, and Senegal [17]. EIV outbreaks have also
been recently reported in Asian and Middle Eastern countries [12]. Multiple cases of
EIV have been described in Japan and Mongolia from horses imported during 2007–2010
from Canada and Belgium during quarantine [28]. In 2012, 3 out of the 18 endurance
horses, with up-to-date vaccine history, imported to Dubai from Uruguay displayed clinical
symptoms of EIV [22]. These horses were further confirmed positive for EIV. These cases
underscore the importance of international/transboundary transport of horses as the
primary route of spread of EIV, even in vaccinated individuals, to EIV-free countries.
Recent widespread outbreaks of EIV either in horses or donkeys have also been well
documented in China [27,29], Kazakhstan [30], and Malaysia [12]. Although occasional
outbreaks of EIV have been reported in South America in the past, there are pointers to a
recent surge in the number of cases over the past few years [22].
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Figure 1. Origin and mo e f transmission of : Aquatic birds serve as the natural reservoir of avian influenza, a
progenitor of EIV. Following infection of a horse, the virus can be spread to other animals in aerosolized droplets by
coughing or through fomite transmission. International transport of horses facilitates the spread of the virus to new
geographical locations, especially during horse events such as racing or shows. Dogs can also become infected and transmit
the virus to other dogs.
Table 1. Selected EI outbreaks in t e past decade.
Country Year Numb r of Animals Infected Animal Source
China 2010/11 NA Horse [31]
Mongolia 2010/11 NA Horse [31]
Algeria 2011 900 Horse [18]
Argentina 2012 NA Horse [22]
Brazil 2012 NA Horse [22]
Chile 2012 NA Horse [22]
China 2012 NA Horse [12]
Kazakhstan 2012 NA Horse [31]
Uruguay 2012 NA Horse [22]
Ireland 2014 18 Horse [32]
Malaysia 2015 25 Horse [33]
Brazil 2015 23 Horse [21]
China 2017 NA Donkey [34]
Uruguay 2018 NA Horse [24]
Chile 2018 NA Horse [24]
Argentina 2018 NA Horse [26]
Senegal 2019 NA Horse and donkey [17]
United Kingdom 2019 NA Horse [35]
China 2020 NA Donkey [29]
NA, not applicable.
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Figure 2. Incidence of EIV in the equine population over the last decade, compiled from OIE ESP on Equine Influenza 
Vaccine Composition reports, 2010 to 2019. (A) Countries are ranked based on the average of incidence rate, i.e., number 
of years reported to OIE ESP over a period of 10 years. (B) Clades responsible for these outbreaks indicated: An incidence 
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from EIV isolates from China, France, Ireland, Niger, Nigeria, the UK, the US, Senegal, 
Figure 2. Incidence of EIV in the equine population over the last decade, compiled from OIE ESP on Equine Influenza
Vaccine Composition reports, 2010 to 2019. (A) Countries are ranked based on the average of incidence rate, i.e., number of
years reported to OIE ESP over a period of 10 years. (B) Clades responsible for these outbreaks indicated: An incidence rate
>50% is classified as high, 50% is moderate, and <50% is low. NA, not available.
Data from the genetic characterization of the HA and neuraminidase (NA) genes from
EIV isolates from China, France, Ireland, Niger, Nigeria, the UK, the US, Senegal, and
Sweden between 2019 and 2020 have been made available. The EIV isolates from China
were characterized as the Florida clade 2 (FC-2) of the American lineage, resembling those
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identified in China in 2015 and 2017, while all other characterized EIV isolates belonged to
FC-1, similar to the 2018 isolates from the US and South America [27].
2. Evolution of EIV
EI is an acute, highly contagious viral disease of equids characterized by the devel-
opment of pyrexia and respiratory signs including coughing and serous nasal discharge;
swollen submandibular lymph nodes may also be observed within a day or two in more
severe cases [36]. EIV, the etiological agent of EI, is an enveloped, negative-sense, single-
stranded, and segmented RNA virus (Figure 3). The biology of EIV, and the roles played
by individual viral protein during the process of viral replication and infection, has been
reviewed [37–50]. The functional relevance of each of the eight genome segments of EIV is
summarized in Table 2.
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Figure 3. Sche atic representation of an influenza A virus (IAV) genome organization and virion structure. (A) The genome
organizatio of the eight n gative-sense RNA gene se ments (PB2, PB1, PA, HA, NP, N , M, and NS) of IAV. All segments
1—8 (as in Table 2) are numbered according to the conven ional represe tation from 3′ to 5′. The black boxes at the end of
each viral segment indicate the oncoding regions (NCR). White boxes show the packaging signals present at the 3’ and 5′
ends of each gene segment. (B) The basic architecture of IAV contains envelope surface glycoproteins HA, NA, and M2 ion
channel protein, all embedded within the host cell-derived lipid bilayer envelope. Immediately underneath the envelope is
a well-organized layer of M1 and NEP proteins surrounding the eight negative-sense viral RNA segments.
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Table 2. EIV segments and their functions.
EIV Segment Functional Class Viral Protein(s) and Proposed Function(s)
1 Structural protein
Polymerase basic 2 (PB2] protein, together with PB1 and PA, forms the RNA-dependent RNA polymerase (RdRp) complex, which is
important for virus replication [51]. Initiates transcription through cap-snatching in conjunction with the proteolytic activity of the PA
subunit [52–54].
2 Structural protein Polymerase basic 1 (PB1) protein, the catalytic subunit of the RdRp complex involved in initiation and elongation of mRNA,complimentary (c)RNA, and genomic vRNA [43,55].
2 + Structural protein PB1-F2, a viral virulence factor known to promote inflammation and cell death while also enhancing viral RdRp activity [56].
3 Structural protein Polymerase acidic (PA) protein has proteolytic activity required for the degradation of host‘s RNA polymerase II (RNAP II) duringinfection [57]. It is also involved in virus assembly [58].
3 + Structural protein PA-X contributes to viral growth and repression of host antiviral and protein synthesis [59,60].
4 Surface glycoprotein Hemagglutinin (HA), an important virus surface glycoprotein that determines host range through binding of virus to susceptible hostcells [61].
5 Structural protein Nucleoprotein (NP) directly binds to newly synthesized viral (v)RNA, providing structural framework for the vRNP complexes [62].
6 Surface glycoprotein Neuraminidase (NA), another important surface glycoprotein, facilitates virus release and efficient spread of the progeny virus fromcell to cell [63,64].
7 Structural protein Matrix protein 1 (M1) serves as the docking site for vRNPs and nuclear export protein (NEP), playing an important role in shuttlingof vRNPs between the nucleus and the cytoplasm. It is also involved in the assembly of vRNPs [65,66].
7 * Surface glycoprotein Matrix protein 2 (M2) serves as a membrane ion channel housed within the lipid bilayers of the virus, where it facilitates theacidification process required for the release of the budding virion [67].
8 Nonstructural protein
Nonstructural 1 (NS1) protein plays a critical role in viral replication and pathogenesis. It suppresses splicing of cellular mRNA and
prevents nuclear export of polyadenylated cellular RNA [68,69]. It also inhibits host innate immune response, particularly the type I
interferon (IFN) system, thereby promoting efficient viral replication and viral cell-to-cell spread [70–72].
8 * Structural protein NEP, in conjunction with M1, facilitates the nuclear export of vRNP complexes to the cytoplasm of infected cells [43].
EIV segment numbers correspond to the protein structures shown in Figure 3A. * splice variant, + Frameshift variant.
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Influenza A viruses (IAV) are believed to have evolved from a common ancestral
progenitor, avian influenza, that diverged into continuous IAV subtypes infecting differ-
ent animal species, including horses and humans [73]. The primary natural reservoirs
of IAV are the aquatic birds, and both EIV and avian IAV share same host cell surface
receptors. Although outbreaks of respiratory diseases in horses resembling influenza were
reported in the 17th century [74] and even earlier [75], the first isolation of an EIV was
that of an H7N7 configuration (subtype 1) in 1956 in Czechoslovakia, designated influenza
A/Equine/1/Prague/56 [76]. This subtype was responsible for EI epizootics that spread to
many parts of the world by the early 1960s. Shortly thereafter, EIV of a second subtype
(subtype 2), designated as influenza A/Equine/2/Miami/63 (H3N8), was isolated from
horses imported to the US from South America [77]. Both EIV subtypes cocirculated in
horses across many parts of the world for over 15 years and reassorted between them
during that time [78–80]. However, the H7N7 subtype stopped producing confirmed
outbreaks of clinical disease in horses after 1979 [74,81]. This virus is now presumed to be
extinct in nature. However, seroepidemiological reports, most recently from Israel [82],
suggest that H7N7 EIV may still circulate; this is discussed further below under.
While the H7N7 EIV seems to have disappeared, the H3N8 EIV still causes major
economic impacts to the equine industry in most parts of the world. Horses travel interna-
tionally more than any other domestic animal, and EIV is the pathogen most frequently
responsible for transboundary equine disease outbreaks following horse importation [2].
Only New Zealand and Iceland have significant horse populations that have remained
continuously free from EI. Some countries, e.g., Australia and South Africa, have erad-
icated EI after past outbreaks, but in Europe, North and South America, and Asia, EI
is generally considered to be enzootic. EI vaccination is encouraged within EI-enzootic
countries, although coverage is limited: e.g., within the US, EI vaccination is recommended
for horses at risk, according to the American Association of Equine Practitioners (AAEP).
Performance horse organizations may adopt more stringent requirements. In EI-free zones
such as Australia, in which EI is a notifiable exotic disease, documented vaccination is
mandatory for horses traveling there, but vaccination of resident horses is forbidden
except in a state of emergency, as it conflicts with serosurveillance for the disease (see
www.animalhealthaustralia.com.au/ausvetplan/, accessed 2 August 2021). DIVA-capable
vaccines are the best choice in those zones, but until the 21st century, there were none
available.
The evolution of EIV H3N8 subtype is driven by antigenic drift [83], the inherent
ability of its HA and NA genes to mutate and accumulate point mutations over time,
similar to what is commonly observed with other IAV (Figure 4). “Antigenic shift” leading
to emergence of new EIV subtypes has not been observed (reassortment between the H7N7
and H3N8 EIV did not change their surface antigens). The H3 HA of EIV has reportedly
drifted at the rate of only 0.8 amino acids/year [84–86]. This rate is less than that of human
IAV, especially the H3N2 subtype. For two decades since its first report, EIV H3N8 subtype
evolved as a single lineage [4]. However, EIV outbreaks of the late 1980s, whose prototype
is influenza A/equine/Suffolk/1989, produced variants of circulating H3N8 leading to
their divergence into an “American” and a “Eurasian” lineage (Figure 4) [38,85]. That is,
geographic distance produced different virus variants in different regions, even though
North America and Europe were not geographically isolated in terms of horse movements.
The American lineage soon spread to Europe, while to this day, the only incursion of
the Eurasian lineage into North America was a single outbreak in Canada in 1990 [87].
These variant lineages were sufficiently different that strains of both were recommended
for inclusion in vaccines [88,89]. With international travel of horses for breeding and
global sports events, both lineages of H3N8 were transported to other continents where EI
outbreaks were linked to either the American or the Eurasian lineage.
Another bifurcation occurred around 2000, as molecular phylogenetic analysis re-
vealed that the circulating H3N8 American lineage strains had evolved into South America,
Kentucky, and Florida lineages (Figure 4) [90]. The Florida lineage further evolved into
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two antigenically distinct clades: Florida clade (FC)-1 and FC-2 (Figure 4) [91]. Both clades
spread internationally and by 2008 had replaced the original American and Eurasian lin-
eages. Curiously, the FC-2 clade has been absent from North America except for horses
recently imported from Europe [92,93]. A variant of the FC-2 clade arose in China in 2011
and appears to have persisted [94]; it will be of interest to watch the further evolution of
this variant.




Figure 4. Schematic of evolution of EIV HA, 1963 to 2021. The major lineages as discussed in the text are indicated, as are 
representative virus strains. Not to scale. 
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described above, but at the level of antigenicity, only a small number appear to be critical 
for emergence of successive lineages and clades. Woodward et al. [95] and Nemoto et al. 
[96] confirmed that changes in antigenic site B seemed to be of greatest importance alt-
hough outbreaks were abetted by an additional change in a different antigenic site and 
that just three substitutions at positions 159, 189, and 227 were critical to the emergence 
of the Suffolk/89 variant that rendered the then-existing vaccines (with 1979–1981 strains) 
antigenically obsolete. Murcia et al. [80] suggested that increased vaccination in the 1980s 
resulted in an EIV evolutionary bottleneck, which was broken by the emergence of Suf-
folk/89 virus. Similarly, FC-1 and FC-2 originally differed by only two antigenically criti-
cal residues, at position 159, again, and position 78 in antigenic site E [91]. Recent studies 
[96,97] have also shown that variation at position 144, which has been occurring in FC-2 
strains since 2011, reduces the cross-neutralization activity of convalescent horse sera by 
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representative virus strains. Not t scale.
Multiple amino acid substitutions i HA have occurred in the course of the evolution
described above, but at the level of antigenicity, only a small number appear to be critical for
emergence of successive lineages and clades. Woodward et al. [95] and Nemoto et al. [96]
confirmed that changes in antigenic site B seemed to be of greatest importance although
outbreaks were abetted by an additional change in a different antigenic site and that
just three substitutions at positions 159, 189, and 227 were critical to the emergence of
the Suffolk/89 variant that rendered the then-existing vaccines (with 1979–1981 strains)
antigenically obsolete. Murcia et al. [80] suggested that increased vaccination in the
1980s res lted in an EIV evolutionary bottleneck, which was broken by the emergence of
Suffolk/89 virus. Similarly, FC-1 and FC-2 originally differed by only two antigenically
critical residues, at position 159, agai , an position 78 in ntigenic sit E [91]. Recent
studies [96,97] have also shown that variation at position 144, which has been occurring
in FC-2 strains since 2011, reduces the cross-neutralization activity of convalescent horse
sera by up to eight-fold. Murcia et al. [80] have shown by a more detailed analysis that the
evolution of the EIV H3 HA since 1963 can be described as successive or cocirculation, with
intrasubtypic reassortment, of 13 distinguishable clades, the most recent 2 being the FC-1
and FC-2. Further, they showed a parallel evolution of all the other viral RNA segments,
with NA and PA genes evolving at rates similar to HA.
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3. EI Vaccines
The two forms of EI vaccines currently marketed in the US are inactivated (killed) and
modified live vaccines [98] (Table 3). However, other EI vaccines licensed for use in horses
in other parts of the world also include recombinant virus vector vaccines and subunit
vaccines [99]. DNA vaccines and other viral vectored vaccines are newer experimental
vaccine technologies (Figure 5). The ability of the host to induce an EIV-specific antibody
response is a correlate of protection that helps to limit the spread of the disease and
viral shedding during an EI outbreak [100,101]. As well as being immunogenic, the
surface glycoproteins (HA and NA) of EIV play vital roles in facilitating infection and viral
spread. EIV-specific neutralizing antibodies (NAbs) directed against HA or NA represent
the first adaptive defensive strategy of the host against virus infection or immunization.
Induction of EIV-specific NAbs helps to neutralize virus infection by preventing virus
attachment to respiratory epithelial cells (HA NAbs) and also helps in blocking virus
release from infected cells (NA NAbs) [102,103]. Equally important for the control of
obligate intracellular pathogens like EIV is cell-mediated immunity (CMI), which involves
cytokine-mediated induction of antigen-specific cytotoxic T-lymphocytes (CTL), natural
killer cells, and macrophages. Below, we evaluate each vaccine line technology with the
focus on the underlining principles behind each vaccine, including its advantages and
disadvantages (Table 4) and field data as a guide for appropriate vaccine selection against
annual EI outbreaks.




Figure 5. EI vaccine technologies: Each EI vaccine system differs in its antigenic composition and structural organization. 
These differences impact on the immunogenicity of the vaccine type. 
4. Inactivated Whole Virus EI vaccines 
An inactivated whole virus EI vaccine consist of a whole EIV strain(s) that have been 
grown in mammalian culture or in the amniotic cavity of fertile hens’ eggs and then de-
natured either by physical (heat or irradiation) or chemical (formalin treatment) means. 
Virus particles in this vaccine are not able to replicate since they are destroyed, but the 
proteins retain antigenic epitopes recognizable by the host immune system and are able 
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Table 3. Selected examples of commercially available EI vaccine technologies.
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Table 4. Advantages and disadvantages of different EI vaccine technologies compared to conventional inactivated-virus vaccines.
EI Vaccine Advantage Disadvantage
Subunit vaccines
Nonpathogenic, hence no risk of infection or clinical signs due to vaccination
Safer, more stable, and easier to handle compared to MLV
The risk of side effects is minimized
Immunity is short-lived and primarily an antibody-based response
It requires adjuvant to improve immunogenicity
Requires booster doses
Recombinant virus vector vaccines
Long-term immune response
Safer, more stable, and easier to handle compared to MLV
High immunogenicity
No or minimal postvaccination reaction or clinical signs (adverse effects)
The immune response can be directed at a specific viral antigen of interest
Easy to produce and transport compared to MLV
Requires booster vaccination
Could lead to the generation of replication-competent virus
Potential of mammalian orthopox to induce tumorigenesis
Risk of pathogenicity in some immunocompromised horses
Presence of pre-existing immunity to the vector
Low titer production
DNA-based vaccines
Nonpathogenic, hence no risk of infection or clinical signs due to vaccination
Inexpensive, safer, more stable, and easier to handle compared to MLV
Easy to store and transport
Similar to recombinant vaccines, the immune response to DNA-based vaccines can be
directed at a specific viral antigen of interest
Unlike MLV vaccines, DNA-based vaccines are heat stable (temperature-insensitive)
Easy to develop and produce using reverse genetics
Could be modified as broad-spectrum vaccines by pooling vaccine plasmids together
to target multiple EIV antigens
DNA-based vaccines may have relatively poor immunogenicity
compared to MLV vaccines
Require booster vaccination
Modified live-attenuated vaccines
Induce strong, long-lasting cross-protection. MLV stimulate the immune system better
than other EIV vaccines
Immunity could last up to 12 months
MLV does not need to be potentiated by adjuvants to induce a robust and prolonged
protective immunity in horses
Elicit local mucosal immunity as well as systemic B- and T-cell proliferation
Can be developed via Reverse genetics
Can be administered via the intranasal route
Cannot be used in immunocompromised horses
Possibility of reversion to virulence
Could cause clinical signs or mild infection in some cases when
not properly administered
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4. Inactivated Whole Virus EI Vaccines
An inactivated whole virus EI vaccine consist of a whole EIV strain(s) that have been
grown in mammalian culture or in the amniotic cavity of fertile hens’ eggs and then dena-
tured either by physical (heat or irradiation) or chemical (formalin treatment) means. Virus
particles in this vaccine are not able to replicate since they are destroyed, but the proteins
retain antigenic epitopes recognizable by the host immune system and are able to evoke
adaptive immunity. Typically, inactivated whole virus EI vaccines need to be administered
multiple times for a stable protective adaptive immune response to be induced. In EIV-
naïve horses, a complete primary course of vaccination requires three doses based on AAEP
guidelines [98], consisting of a priming dose, a booster within 3–6 weeks, and a second
booster within 5 months. Thereafter, annual boosters are recommended for most horses and
twice-annual boosters for horses at risk of exposure (i.e., horses traveling for performance
or breeding). Cullinane et al. [104] discuss the relevant vaccination guidelines of the OIE,
Federation Equestre Internationale (FEI), and International Federation for Horseracing
Authorities (IFHA) and show experimentally that, for shipment of young horses up to 4
years of age, a booster within 90 days before shipment is best, with an optimal interval
of 14 days between booster and shipment. The nature of the immune response is often
times similar to that of the natural infection, but this vaccine preferably instructs for the
development of humoral immunity, with minimal CMI. In young horses, the serum anti-
body titer declines rapidly after the primary two vaccinations, and as a result, these horses
may not be adequately protected for a period before the third booster dose [105–107]. This
period between the second and third vaccinations when young horses become vulnerable
is referred to as the immunity gap [106,108]. Closing the immunity gap is a concern, be-
cause this is the age in which performance horses from different stables are comingled for
training, presenting elevated risk of disease exposure. Different vaccines and vaccination
schedules have shown mixed success [109–111]. Maternal antibody interference with foal
EIV vaccinations is a concern, especially with inactivated virus vaccines [110,112–115], such
that the recommended age for the first (priming) dose is typically 6 months in foals whose
dams are expected to be EI-seropositive. Fortunately, in such foals, maternal antibodies
from colostrum are protective, and EI is seldom a problem until after 6 months of age.
One major drawback of inactivated vaccines is that they tend to be less immunogenic
and, as a result, require the addition of an adjuvant to achieve protective immunity [116].
Inactivated whole virus EI vaccines are adjuvanted with the goal of enhancing or boost-
ing the horse’s specific immune responses. An adjuvant is a chemical component of an
inactivated vaccine that potentiates the immune responses to interact either physically or
chemically with the antigenic component of the vaccine. Several chemical ingredients have
been tried as adjuvants in inactivated EI vaccine compositions, and aluminum-based adju-
vants, particularly aluminum hydroxide, continue to be widely used [117–119]. Aluminum
hydroxide preferentially drives TH2-type, humoral-mediated immune responses [120,121].
Although protection against EIV is mainly by virus neutralization by vaccine-induced
NAbs [122], effective elimination of EIV-infected host cells requires the protective effects of
CMI. It is not clearly understood whether aluminum hydroxide adjuvanted inactivated
EI vaccines can stimulate CMI. One study with an inactivated whole virus EI vaccine
adjuvanted with aluminum phosphate or aluminum hydroxide failed to induce CMI [117].
However, in another study, stimulation of CMI was observed following immunization of
ponies with Duvaxyn IE-T Plus, an inactivated whole virus EI vaccine adjuvanted with
aluminum hydroxide [119]. The uncertainty surrounding CMI stimulation by inactivated
whole virus EI vaccine adjuvanted with aluminum hydroxide has necessitated the evalua-
tion of new adjuvants to augment protective immunity with this model of EI vaccine, and
squalene-based adjuvants are now in use.
Inactivated whole virus EI vaccines have been reported to elicit immune responses
to both the antigenically variable regions on the viral surface glycoproteins (HA and
NA) as well as the more conserved viral proteins such as the NP and M1 matrix protein,
believed to induce some level of cross-protection [99,123]. More recently, Pavulraj and
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coworkers demonstrated that immunization of horses with Calvenza-03 EIV/EHV®, an
inactivated EI vaccine containing Carbimmune® as an adjuvant, effectively stimulates
protective EIV-specific humoral and CMI responses in vaccinated horses [124]. Specifically,
the authors showed that a booster immunization of horses with Calvenza-03 EIV/EHV®
maintained protective antibodies as measured by single radial hemolysis (SRH) for 6
months in vaccinates that received homologous first vaccine dose and 10 weeks when
horses received a heterologous first vaccine dose. They also observed a significant increase
in EIV-induced interferon-gamma (IFN-γ)-secreting peripheral blood mononuclear cells
(PBMC), a marker of CMI in immunized or infected horses, in Calvenza-03 EIV/EHV®-
immunized horses, which was attributable to the presence of Carbimmune® adjuvant in
the vaccine. Taken together, a potent inactivated whole virus EI vaccine should contain an
adjuvant that can prime the induction of not only a robust, long-lived NAb response but
also a strong CMI response that is capable of offering cross-protection against antigenically
different strains of EIV.
5. Subunit EI Vaccines
Unlike inactivated whole virus EI vaccines, subunit EI vaccine technology incorpo-
rates only EIV antigenic fragments (HA or NA) to elicit a protective immunity instead
of the entire virus. These antigenic fragments of EIV are then encapsulated in colloidal
particles as an antigen delivery system to the host immune system. Of the numerous
vesicles available for presenting antigenic components to the host immune system [125],
the use of the immunostimulating complexes (ISCOMs) and ISCOMATRIXTM are pre-
dominant. ISCOMs and ISCOMATRIXTM possess an in-built adjuvant (Quil A saponin)
and, consequently, have been found to be more immunogenic than other colloidal systems
such as liposomes and protein micelles [126]. ISCOMs were first described by Morein and
coworkers in 1984 as a novel structure for antigenic presentation of membrane proteins
from enveloped viruses with potent immunogenic activity [127]. ISCOMs are particulate
antigen delivery systems composed of antigen, cholesterol, phospholipid, and Quil A
saponin [128], while ISCOMATRIXTM has essentially similar composition but with the
antigenic component combined at a later step to create the vaccine [129]. The antigen
uptake, processing, and presentation by antigen presenting cells (APCs) is believed to be
similar after immunization with ISCOMATRIX™ or ISCOM-based vaccines [126,130,131].
Antigens adjuvanted to ISCOMs/ISCOMATRIXTM are processed by both endogenous and
exogenous pathways and presented to major histocompatibility complex class I (MHC
I) and MHC II molecules, respectively [132,133]. Many studies have demonstrated the
safety and ability of ISCOMs/ISCOMATRIXTM to induce strong antigen-specific humoral
and CMI to a wide array of antigens in different animal models [134–137]. The overall
adjuvant activity of the Quil A saponin moiety of ISCOMs/ISCOMATRIXTM has been
approved for veterinary use [134,138], but their use in human vaccines has been restricted
due to undesirable side effects, such as local reactions, hemolytic activity, and systemic
toxicity [138].
The immunity induced by conventional inactivated and subunit EI vaccines in the
horse is usually short-lived, primarily an antibody-based response. This has necessitated re-
cent vaccine strategies to aim at the possibility of inducing robust EIV-specific antibody- and
T-cell-driven long-term immune responses. Several studies have investigated the efficacy
and safety profiles, duration of immunity, immunity gap, and the level of protective immu-
nity evoked by ISCOM/ISCOMATRIXTM vaccine in horses following experimental chal-
lenge infection with a wild-type (WT) EIV [104,105,108,139–146]. While most of these stud-
ies investigated TH2 antibody-based response, studies focused on TH1-mediated immune
protection following vaccination with EIV-ISCOM/ISCOMATRIXTM in horses are limited.
In one study, Paillot and coworkers investigated the EIV-specific protective immune re-
sponses in ponies vaccinated with an ISCOM-EIV vaccine (EQUIP F) containing both EIV
H7N7 (A/eq/Newmarket/77) and H3N8 (A/eq/Borlänge/91 and A/eq/Kentucky/98)
strains before an experimental challenge with A/eq/South Africa/4/03 [146]. Findings
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from their study showed that the subunit vaccine induced a balanced TH1/TH2 immune
response mediated by increased antibody as measured by SRH and EIV-specific IFN-γ
synthesis that correlated with reduced clinical severity and virus shedding in vaccinated
ponies compared to the controls. Further studies are needed to fully characterize the cell-
mediated responses of horses immunized with EIV-ISCOM/ISCOMATRIXTM and their
roles in immune protection against EI.
6. Recombinant Virus Vector Vaccines
For decades, scientists have been researching approaches for introducing a small
immunogenic segment of an infectious virus into a safe, larger-coding virus in an attempt
to induce a long-term protective immunity against the foreign gene in the target host
upon immunization [147–149]. Viral vectors are viruses that can be genetically modified
to encode gene segments of another virus that is immunogenic for the purpose of vaccine
production. Viral vectors have the potential for applications in both gene therapy and
vaccine production. The concept of recombinant virus vector vaccine is different from
that of inactivated whole virus and subunit EI vaccines that predominantly stimulate the
humoral arm of the host adaptive immune response. Recombinant viral vector vaccines
deliver antigens to the intracellular compartment in their targets, stimulating a robust
and long-lasting CTL response in the process, leading to the elimination of virus-infected
cells [150]. The development of viral vectors is a great biological safety concern, and selected
viral vectors for vaccine development have to be proven safe to gain public acceptance. As a
result, most viral vectors are replication-deficient and, in most cases, genetically engineered
to eliminate pathogenicity, making them unable to cause any harmful effect in immunized
individuals. Experimentally, vaccinia virus and adenovirus are two of the most commonly
used viral vectors because of their capacities for gene insertion, capability of attenuation
in mammalian cells, and their ability to induce robust CMI, specifically, the TH1-directed
response against the expressed foreign antigen following immunization.
A robust protective immunity, comprising EIV-specific antibody, measured by SRH,
and IFN-γ+ cells, was reported in ponies vaccinated twice (at 35-day interval) with a li-
censed ProteqFlu® canarypox vector vaccine (Boehringer Ingelheim, Ingelheim, Germany)),
expressing the HA genes of influenza A/eq/Newmarket/2/93 and A/eq/Kentucky/94
(H3N8), following an experimental challenge with a representative circulating equine
A/eq/Newmarket/5/03 strain [151]. In a similar study, ponies that were immunized with
a canarypox vector vaccine with the same antigenic composition demonstrated an early on-
set of induction of anti-EIV antibody response with protection that lasted 6 months follow-
ing challenge with equine A/eq/Kentucky/91 H3N8 or A/equine/Ohio/03 H3N8 [152].
Although the HA of IAV is not a major CTL target, a strong EIV-specific HA-antibody
induced by canarypox vector vaccines offers the first line of an adaptive defense to block
viral infection, especially with a homologous virus strain. The ProteqFlu® canarypox-vector
vaccine, by virtue of expressing only HA, is also the only currently licensed DIVA-capable
vaccine, and for that reason, was chosen for exclusive use in Australia to contain their 2007
EIV epizootic [11]. In situations where the circulating field strain of EIV has evolved and
undergone significant mutation in their HA epitopes, this HA-based approach may offer
little or no protection. However, the NP of IAV are a major target of immunodominant
CD8+ T-cell responses [153], and immunization of ponies with a modified vaccinia Ankara
vector vaccine expressing NP of A/equine/Kentucky/1/81 H3N8 (Eq/Ky) induced high
levels of EIV-specific serum IgGa and IgGb as well as virus-specific lymphoproliferative
responses in all vaccinated ponies [154]. Thus, a recombinant viral vector vaccine express-
ing any EIV protein that contains immunodominant CTL epitopes, such as the M1 and
NP, would offer a more improved alternative to strengthen both the EIV-specific antibody
and T-cell responses already provided by HA-expressing viral vector vaccines. Further
work is required to investigate immunogenic CTL epitope-rich regions within the most
antigenic viral proteins of EIV that can be co-expressed in recombinant viral vector systems
for T-cell-mediated multistrain EI vaccine development.
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A presumed limitation to the use of viral vector vaccines is the presence of pre-
existing immunity to the vector, itself. For instance, the acquisition of immunity against the
poxvirus component of vaccinia-vectored vaccine may reduce the vaccine’s effectiveness
in later vaccinations [155]. Vaccinia virus presents human safety issues, and efforts are
being continuously made to improve vaccinia-based virus vectors. The abortive infection
produced by canarypox, an avipoxvirus, reduces the vector-directed immune response
as well as enhances the safety of canarypox-vectored vaccines [156]. For the horse, the
canarypox virus vector vaccine appears to be well-tolerated in the host for immunization
against West Nile virus [157–159]. Other potential vectors, e.g., equine adenovirus, present
opportunities for development. There are also prospects for indirect application of viral
vector technologies, e.g., plant production of artificial virus-like particles (VLPs) containing
influenza antigens to be used as immunogens [160].
7. DNA-Based EI Vaccines
Recombinant DNA technology has made important contributions to both human
and animal health, especially in the field of vaccinology. This vaccine strategy involves
the injection of plasmid DNA encoding an antigen into host cells, where it can undergo
translation, activating the CD4+ and CD8+ cells for an enhanced antigen-specific antibody
and CTL response. Like the recombinant-vector vaccine, this vaccine technology is advan-
taged compared to the inactivated-virus and subunit systems, because it allows for the de
novo synthesis of the immunogen, over a period of time, within the host cell following the
injection of the DNA plasmid. This allows for the antigen presentation in its most native
conformation [161,162] and the appropriate expression of both MHC class I and MHC class
II molecules [163,164] similar to that in natural virus infection but devoid of risk of reversal
to virulence, as with a live virus [165]. The DNA technology facilitates rapid updating by
site-directed mutagenesis, which is particularly relevant for influenza vaccines. Messenger
RNA-based vaccines work on the same principle and, as this technology has advanced
for human applications, including their recent use to combat Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019
(COVID-19), it may soon come into veterinary applications.
The application of DNA technology to EI vaccines has been ongoing experimentally
for some time, and it is gradually gaining acceptance as a possible basis for new generation
vaccines in horses. In a study by Ault and colleagues, the ability of a recombinant DNA
vaccine expressing HA antigen(s) from EIV H3N8 strains, either in a monovalent or
multivalent composition, was assessed for its ability to induce protective immune responses
against homologous EIV challenge in vaccinated ponies. Ponies were either immunized
with a monovalent DNA expressing the HA gene of A/Equine/Ohio/03 H3N8 or a
trivalent DNA mix of HAs of A/Equine/Ohio/03 (H3N8), A/Equine/Bari/05 (H3N8),
and A/Equine/Aboyne/05 (H3N8) before challenge with A/Equine/Ohio/03 (H3N8) WT.
All vaccinated ponies showed a similarly elevated EIV-specific antibodies, as measured
by hemagglutination inhibition (HI) and SRH, which conferred protection against clinical
disease and nasal shedding of virus compared to the sham-vaccinated controls [166].
The magnitude of this response was similar to that reported for both modified-live and
canarypox-vectored vaccines but was of a slow onset. Pioneering works in the field have
previously demonstrated that there is a benefit to extending the duration between the
prime and booster doses of DNA vaccine expressing HA of EIV in mice for a stronger
protective immune response [167]. Therefore, the success of a DNA-based vaccine for the
control of EI would depend on the optimization of the time between the initial and booster
DNA vaccinations for a more potent effect in vaccinated horses.
The characteristics of the induced immune response in ponies that received the HA
DNA vaccination indicate increases in EIV-specific IgGa and IgGb antibody [168,169] and
IFN-γ [169] responses, which are correlates of protection from EI, even in the absence of
local mucosal IgA [168]. Although HA-based DNA vaccines were able to offer protection
from clinical disease despite the lack of IgA stimulation, induction of mucosal IgA has a
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desirable effect in the control of influenza virus before it enters systemic circulation [170].
In addition, the induction of virus-neutralizing IgA represents a valuable correlate of
cross-protection against antigenically different IAV [171], and during transport across the
mucosal epithelium, IgA may also help to neutralize intracellular viruses [172]. Although
the immunization of ponies with HA-based DNA vaccines clinically protects from EI due
to the enhancement of adaptive immune responses other than IgA, factors that favor the
induction of IgA in the respiratory mucosa should be encouraged during the development
of DNA vaccines. This will go a long way to prevent nasal shedding of the virus and help
to curtail the possibility of EIV transmission to naïve horse populations.
8. Modified Live-Attenuated Vaccines (MLV)
This technology involves the manipulation of a live virus under laboratory conditions
such that it can no longer cause harmful effects but retains its immunogenicity upon
immunization. MLV can induce strong, long-lasting cross-protection by eliciting local
mucosal immunity as well as systemic B- and T-cell proliferation. As whole intact viruses,
they also present CTL epitopes on NP/M proteins which should facilitate cross-protection
against heterologous WT strains. MLV mimics a live IAV in vivo following administration.
They are recognized and presented to the APC like a live virus capable of continuous
antigenic stimulation of the host’s mucosal and systemic immune systems. This helps to
facilitate memory cell production. Unlike the conventional killed virus vaccines, an MLV
does not need to be potentiated by adjuvants to induce a robust and prolonged protective
immunity in horses. During development of an MLV, the level of attenuation should be
fine-tuned such that virus is able to evoke protective immunity in the host while still
maintaining safety. As a result, the most important consideration for an MLV is safety,
especially in immunocompromised individuals. The attenuation must be safe and not able
to revert to virulence for public acceptance. To further minimize the possibility of reversion,
the live vaccine organism should be self-limiting and incapable of spreading spontaneously
from vaccinated to nonvaccinated animals [173]. Due to these safety concerns, and with
the example of human polio in mind, some countries forbid MLV veterinary vaccines, all
together. The two commonly used approach for the generation of an EI MLV are the cold-
adaption (ca), rendering the virus incapable of replication at normal host body temperature,
and the reverse genetic system.
Live-attenuated influenza vaccine (LAIV) based on the generation of temperature
sensitive (ts), ca, strains of EIV were first tested by Holmes et al. [174,175]. Flu Avert®
I.N. Vaccine (Merck Animal Health Inc., New Jersey, USA), the first modified-live virus,
intranasal EI LAIV, was licensed in 2000 and remains on the market in the US. This vaccine
was shown to be safe, phenotypically stable, and effective in protecting vaccinated ponies
against either homologous or heterologous EI challenge [173,176,177]. It was also safe and
effective in ponies with exercise-induced immunosuppression [178]. This clinical protection
was achieved despite induction of only low or even undetectable serum antibody titers,
suggesting that the ts/ca virus induced mucosal immunity directly in the respiratory tract.
This vaccine was ca by serial passage of the WT influenza A/equine//Kentucky/91 virus
in embryonated eggs with step-wise reduction of the incubation temperature to 26 ◦C [179].
Consequently, the attenuated virus can replicate in the upper respiratory tract (URT) of
horses where immune responses are induced but not in the warmer environment of the
lower respiratory tract (LRT) of the host [180]. This MLV vaccine had the limitation that a
single dose reduced but did not eliminate WT virus shedding following challenge: i.e., it did
not provide sterile immunity. In a more recent study, Tabynov and coworkers investigated
the duration and protective immunity of a ca, modified-live attenuated EI vaccine in a
group of yearlings. Two groups of horses, comprising of a prime group and a booster
group, were vaccinated with a ca equine A/HK/Otar/6:2/2010 H3N8, and protection
from clinical disease was evaluated, relative to the control group, upon challenge with
either homologous or heterologous EIV. The authors demonstrated that the vaccine is safe
and offers a protective immunity either in the prime or the booster group, with protective
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immunity lasting for 12 months, even against heterologous EIV challenge [181]. This
vaccine induced EIV-specific HI titers that correlated with reduced clinical and virologic
burdens of EI.
9. Reverse Genetics to Generate EIV Live-Attenuated Influenza Vaccines (LAIV)
Reverse genetics approaches to generate recombinant IAV, including EIV [182,183], have
been well-described in the literature, including those for the development of LAIV [184–189]
(Figure 6). The most commonly used approach to generate recombinant IAV is based on the
use of ambisense plasmids that allow the expression from the same plasmid of the negative-
stranded vRNA and the positive-stranded mRNA from transfected cells (Figure 6A). In this
rescue system, a cDNA copy of each of the vRNA segments are cloned in an ambisense
plasmid containing, in opposite orientation, cellular RNA polymerase I (hPol-I) and RNA
polymerase II (Pol II) cassettes (Figure 6A). The RNA Pol I cassette directs, under a hPol-I
promoter and a murine terminator sequences, the synthesis of vRNAs. In opposite ori-
entation, the RNA pol II cassette directs, under a Pol-II promoter and the bovine growth
hormone (BGH) polyadenylation signal, the synthesis of viral proteins required to initiate
viral genome replication and gene transcription (Figure 6A). Once the eight viral segments
are cloned in the ambisense plasmid, the eight plasmids are cotransfected into cocultures of
human 293T and canine Madin–Darby Canine Kidney (MDCK) cells and rescued recombi-
nant IAV are amplified in either MDCK cells or chicken embryonated eggs from the tissue
culture supernatant from transfected cells (Figure 6B).
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Schematic illustration of the ambisense plasmids to generate recombinant EIV: Ambisense plasmids
for the rescue of recombinant EIV contain the human polymerase I promoter (hPol-I, gray arrow)
and the mouse polymerase I terminator (T, gray box) to regulate the expression of the negative-sense
vRNAs. In the opposite direction to the Pol-I cassette, the polymerase II-dependent promoter (Pol-II,
black arrow) and the bovine growth hormone polyadenylation sequence (BGH, black box) produce
viral proteins. The vRNAs generated from the Pol-I cassette are recognized by the EIV polymerase
subunits PB2, PB1, and PA that, together with the viral NP, form the viral ribonucleoprotein (vRNP)
complexes involved in viral genome replication and gene transcription. Transcription of the vRNA
results in viral mRNA and protein production. Replication of vRNAs results in complementary
(c)RNAs for the amplification and synthesis of new vRNAs that are incorporated into nascent virions.
(B) Generation of recombinant EIV using plasmid-based reverse genetics: Cocultures of human 293T
and MDCK cells are cotransfected with the eight ambisense plasmids containing the EIV PB2, PB1,
PA, HA, NP, NA, M, and NS segments. EIV generated from transfected cells is amplified in fresh
monolayers of MDCK cells or in chicken embryonated eggs. (C) LAIV based on truncations of EIV
NS1 protein: Schematic representation of WT and 1–73, 1–99, and 1–126 NS1 truncated NS viral
segments. Black lines represent stop codons introduced to truncate NS1. Lines at the end of the NS
segment indicate the 3’and 5’ NCR. (D) Schematic representation for the development of an EIV
bivalent LAIV: The mutations responsible of the ts, ca, and att phenotype of the human A/Ann
Arbor/6/60 H2N2 MDV LAIV were introduced into the PB2 (N265S) and PB1 (K391E, E581G and
A661T) viral segments of A/equine/Ohio/1/2003 H3N8 WT (Ohio/03 WT) to generate the FC-1 EIV
monovalent LAIV (Ohio/03 LAIV). The backbone of Ohio/03 LAIV was used as an MDV to generate
a recombinant virus containing the HA and NA glycoproteins of the FC-2 A/Richmond/1/2007
H3N8 WT (Rich/07 WT) to develop the FC-2 EIV monovalent LAIV (Rich/07 LAIV). The bivalent
EIV LAIV was developed by combining the monovalent Ohio/03 and Rich/07 LAIVs.
10. EIV LAIVs Based on Truncations of the Viral NS1 Protein
IAV NS1 is a multifunctional protein with several roles during viral replication [70,190–195].
One of the most important and characterized functions of IAV NS1 is to counteract the
antiviral innate immune response induced during viral infection [70,194,195]. EIV NS1,
similar to other IAV, is able to efficiently counteract the interferon (IFN) response [196].
Recombinant IAVs with deletions, truncations, or modified NS1 proteins have been shown
to represent an excellent option for their implementation as LAIV since they are not able to
replicate in IFN-competent hosts due to the lack or altered anti-IFN function of NS1. The
use of IAV with modified NS1 proteins as LAIV has been proposed for swine [197–200],
avian [201–205], canine [206], human [207–209], and equine [182] IAV based on their safety,
immunogenicity, and protective/effective profile. Importantly, a correlation between
the length of IAV NS1 protein and attenuation, immunogenicity, and protection efficacy
in vivo has been reported. Likewise, recombinant influenza B virus (IBV) containing a
deletion and/or truncations of the viral NS1 protein has also been proposed as LAIV for
the treatment of IBV infections [210].
Using reverse genetics for influenza A/eq/KY/5/02 H3N8, Quinlivan et al. gen-
erated recombinant EIV containing 1–73, 1–99, and 1–126 amino-acid-long NS1 proteins
(Figure 6C) that were tested for safety in mice [182]. Contrary to previous studies with other
IAV, Quinlivan et al. found that, in the case of EIV, the length of the NS1 protein did not
correlate with the level of attenuation [182]. In the EIV strain used in this study, the virus
with the shortest NS1 protein [1–30,36–50,73–100] was less attenuated than those encoding
larger NS1 proteins (e.g., 1–99 and 1–126) [182]. Importantly, vaccination in horses demon-
strated that aerosol or intranasal vaccination with the NS1 truncated EIV A/eq/KY/5/02
H3N8 were safe, and horses vaccinated with the EIV NS1–126 A/eq/KY/5/02 H3N8 were
protected against developing fever and clinical signs of infection and experienced reduced
quantities of challenge A/eq/KY/5/02 H3N8 EIV WT compared to mock-vaccinated
controls, suggesting the feasibility of implementing these NS1 truncated EIV as safe, im-
munogenic, and protective LAIV against EI in its natural host [211].
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11. LAIVs Based on ts, ca, and att EIV
In 2018, Rodriguez et al. described the generation of an EIV LAIV for the FC-1 Ohio/03
H3N8 [183]. This clade 1 EIV LAIV was generated by introducing the mutations responsible
for the ts, ca, and attenuated (att) phenotype of the human master donor virus (MDV)
A/Ann Arbor/6/60 H2N2 [212–215] into the polymerase PB2 (N265S) and PB1 (K391E,
E581G, and A661T) segments of EIV Ohio/03 (Figure 6D). The mutations of the human
MDV A/Ann Arbor/6/60 H2N2 were able to transfer the same ts, ca, and att phenotype to
the EIV Ohio/03 [183]. When tested in mice, the Ohio/03 LAIV was safe, immunogenic,
and able to protect, upon a single intranasal dose, against Ohio/03 WT infection [183].
Importantly, its safety, immunogenicity, and protective efficacy profile was also observed
in horses, suggesting the feasibility of implementing this LAIV for the control of FC-1
EIV in horses [183]. Since the OIE currently recommends that both FC-1 and FC-2 EIV
should be incorporated in any EIV vaccine, a year later, Blanco-Lobo et al. developed a
FC-2 monovalent EIV LAIV and, also, the first bivalent EIV LAIV for the protection against
FC-1 and FC-2 EIV based on the use of reverse genetics approaches [216]. To that end,
Blanco-Lobo et al. used the internal genes of the Ohio/03 LAIV as a MDV [183] and the
HA and NA of A/equine/Richmond/1/2007 H3N8 (Rich/07), a representative FC-2 EIV,
to generate the FC-2 EIV LAIV [216]. To generate the bivalent EIV LAIV, Blanco-Lobo et al.
used a previously described approach to generate a bivalent canine influenza virus (CIV)
LAIV [217] that consisted of mixing the two FC-1 and FC-2 monovalent EIV LAIV and
demonstrate how vaccination of horses with the bivalent EIV LAIV was safe and able to
protect, upon a single intranasal dose administration, against challenge with both FC-1
A/equine/Kentucky/1/1991 H3N8 and FC-2 Rich/07 H3N8 EIV in horses [216].
12. Vaccine Efficacy Testing
The first generations of EI vaccines were killed virus preparations that included both
the equine/H7N7 and equine/H3N8 subtypes. Efficacy was assessed by seroconversion of
horses following vaccination [218]. Typically, such testing is done by inoculation of cohorts
of horses (suitably blocked for factors including breed, age, sex, prevaccination titers)
with one dose, or two doses usually 1 month apart, and blood collection at 1- or 2-week
intervals. Peak response is typically 2–3 weeks after each dose. Duration-of-immunity
studies feature successive blood collections for 6–12 months. A low-titer sentinel cohort
should be maintained with each vaccination cohort to alert if there was incursion of WT
EIV in the study population. With conventional killed-virus vaccines, inoculation is by
intramuscular injection into the horse’s neck muscles.
Seroconversion is widely assessed by using the HI test [219]. HI testing is known for a
deficiency of reproducibility, particularly interlaboratory reproducibility [220]. Alongside
mechanical error, two other factors are recognized: First, sera contain nonspecific inhibitors
of hemagglutination. These are of three classes, α, β, and γ, varying in heat-lability
and virus neutralization activity. Equine serum, in particular, contains high levels of a
heat-stable, virus-neutralizing γ-inhibitor called α-2 macroglobulin [221,222], producing
false-positive results. This is removed from sera before HI testing, with different levels of
effectiveness, by various treatments including heat (56 ◦C), receptor-destroying-enzyme
(RDE), kaolin adsorption, or trypsin–periodate treatment [223]. Curiously, the nonspecific
inhibitor of EIV H7 HA is harder to eliminate than that of EIV H3 HA and requires
trypsin–periodate, the most vigorous treatment, to assure an absence of false-positive
results when testing for EIV H7 antibodies [224]. For this reason, periodate or RDE are
the serum treatments recommended by the OIE for HI testing of equine sera. Second,
it was found that the equine/H3 component of vaccines was much less immunogenic
than the equine/H7 component. This is believed to be due to more extensive addition
of carbohydrate sidechains masking antigenic determinants. Adjuvants such as alum or
squalene help overcome this problem, but in general, postvaccination serum antibody
titers to the equine/H3 component are unimpressive. For HI testing, a virus antigen
pretreatment, Tween80/ether [225], is sometimes adopted [218] that amplifies the apparent
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antibody titer by disrupting whole virus into lipid micelles. Tween80/ether treatment
introduces problems of batch-to-batch variation and lack of homogeneous stability that
contribute to the reproducibility problems of HI testing, and there is no reliable conversion
factor between titers obtained using ether-treated antigen and those obtained without. The
best procedure is to test all samples side-by-side. Furthermore, the increased sensitivity
tends to obscure differences in antibody reactivity between virus strains [226]. By HI,
seroconversion is conventionally defined as four-fold increase in postvaccination titer over
the prevaccination titer. A titer of 1:64 is conventionally viewed as clinically protective,
but in horses, this has not been rigorously established, especially against challenge with
heterologous strains. It is sometimes erroneously assumed that an HI titer is equivalent to
a NAb titer. There is a good correlation [227]; still, the latter should be determined by a
neutralization assay, whereas HI is a binding assay [228].
As an alternative to HI testing, the SRH test is often used [229]. This is more re-
producible than the HI test [230] and has the further advantage that titers vary linearly
by measure of the area of the zone of hemolysis instead of by HI’s successive two-fold
increases that require log-transformation for statistical analysis. Using SRH, titer thresholds
are more precisely correlated with clinical protection (prevention of disease, 85 mm2) or vi-
rological protection (prevention of virus shedding, also called sterilizing immunity) against
homologous (150 mm2) or heterologous (up to 205 mm2) virus strains [88,107,231]. The
SRH test has its own technical problems (e.g., different viruses may require reoptimization
of the relative quantity of erythrocytes), but these optimization issues seem to have little
effect on the titers finally obtained. Seroconversion is conventionally defined as an increase
of at least 25 mm2 or 50%, whichever is smaller, in area of the zone of hemolysis. Other sero-
logical assays (reviewed in [232]) are sometimes used, although generally not for efficacy
testing. These include virus neutralization [97,227] and enzyme-linked immunosorbent
(ELISA) [233] assays.
Once equine antibody isotypes were characterized, it was discovered that conventional
killed-virus vaccines adjuvanted with alum mainly induced serum antibodies of subclass
Ig(T) [234], i.e., IgG3/5 in the modern nomenclature [235]. This differed from natural EIV
infection of horses, which induced mainly antibodies of the IgGa/b (IgG1/4/7) subclasses;
furthermore, Ig(T) antibodies were shown to be less protective than IgGa/b antibodies.
Additionally, the alum-adjuvanted killed virus vaccine was incapable of generating a
mucosal IgA response characteristic of natural infection and was thought to be poor
at stimulating cell-mediated immune responses: more recent work suggests that alum
adjuvants stimulate TH2 responses but inhibit TH1 responses (reviewed in [116]). These
factors offered partial explanations for the anecdotal experience of veterinarians in the early
1990s, that the available EI vaccines were of limited effectiveness, and contributed to the
push for the development of vaccine technologies that would provide improved protection:
ISCOM, MLV, and recombinant-canarypox vaccines that came to market between 1995 and
2005.
The development of an MLV for EI triggered a re-evaluation of standards for vaccine
efficacy testing, because this MLV was administered by the intranasal route and was
notably poor at induction of serum HI antibodies. It was predicted that this vaccine would
be more effective at induction of mucosal antibodies and cytotoxic T-lymphocytes in the
respiratory tract, although this has actually not been conclusively demonstrated. Instead,
efficacy was demonstrated by experimental challenge of vaccinated horses with WT EIV
and observation of clinical and virological parameters. That is, protective efficacy was
demonstrated by actual protection instead of by seroconversion, which is a correlate of
protection. In the US, this has become accepted as satisfactory and, indeed, desirable
evidence for vaccine license approval when conducted according to US Department of
Agriculture (USDA) requirements.
Experimental challenges of horses have their own problems: (1) only well-isolated or
purpose-bred herds are likely to have no exposure to EI, and when challenged, even weakly
seropositive horses may show evidence of protection without vaccination; (2) horses are
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not genetically homogeneous. While all equids appear to be susceptible to EI, it is possible
that some breeds (donkeys) are more severely clinically affected than others; (3) some
clinical signs can be measured with reasonable accuracy, e.g., body temperature and heart
rate. Others are more subjective, e.g., lung auscultation sounds, demeanor, severity of
nasal discharge. A large-animal veterinarian, preferably blinded to vaccination status,
should be part of the research team, to make these judgements and provide therapies, if
needed; (4) virological assessment is based on virus content detected in nasal or (ideally)
nasopharyngeal swabs. Horses frequently object to the swabbing procedure with the result
that the quality of the swab sample may vary from horse to horse and day to day, affecting
the accuracy of virus quantitation; and (5) the ideal solution to these problems is to have
large numbers of horses in vaccine and control groups. That is expensive and likely to
be limited by the stall capacity of the animal facility. The outcome is that the statistical
power of such experiments may be less than desired. A successful challenge is one where
the clinical and virological differences between vaccinates and controls is unequivocal.
To overcome these problems, small animal models for testing EI vaccine efficacy have
been developed (e.g., [236,237]), but testing in the actual target species of interest remains
desirable.
The procedure for experimental challenge of horses is that described by Mumford
et al. [238]. Those authors showed that aerosol inhalation was more effective than intranasal
intubation as the route of virus administration and that a dose of 106 50% egg infective dose
(EID50) units was needed for full expression of typical clinical signs. This is presumably
far greater than the natural infection dose, arguing that some virulence for horses may
be lost by egg adaptation. Using this or similar protocols [239], influenza-naïve horses
will typically exhibit pyrexia, coughing, and serous nasal discharge by the second day
following infection. Virus shedding is sometimes detectable on the first day following
infection and typically reaches its peak on the second or third days. Shedding then declines,
and live virus may become undetectable by days 6 to 8 following infection, while vRNA
detectable by qRT-PCR may persist for 10 days or even longer. There have been reports
of RT-PCR-positive swabs beyond day 15 [240], although these horses are presumably
no longer contagious. Severity of clinical signs—pyrexia, tachypnea, tachycardia, cough,
mucopurulent nasal discharge, anorexia—may peak around days 2–3, or there may be
a second peak around days 4–5 triggered by secondary bacterial infections. Swelling of
submandibular or retropharyngeal lymph nodes may be detected, but in our opinion,
this is an outcome of the immune response and may be apparent in otherwise clinically
protected horses. Generally, horses will have completely recovered from disease signs and
be clinically normal by day 10. There may be considerable horse-to-horse variation. In
particularly severe cases, there may be bronchopneumonia with coarse crackles detected
by lung auscultation, and it is possible for bronchopneumonia to become life-threatening
without antibiotic treatment. In experimental settings, animal welfare considerations may
demand antibiotic therapy before clinical signs become so severe. Some laboratories in-
stigate prophylactic antibiotic treatment prior to challenge to avoid secondary infections,
all together. Along with virus shedding quantified by qRT-PCR [241] or by EID50 assay,
measurable clinical signs such as pyrexia and tachycardia can be statistically analyzed. To
quantify the more subjective clinical signs for statistical analysis, our laboratories use an
established but essentially arbitrary scoring system shown in Table 5 [173]. Alternative scor-
ing systems can be envisioned. Baseline data for each horse should be collected in the days
immediately preceding challenge, after horses have become settled inside the facility. Once
horses have had clinical interventions postchallenge, e.g., antibiotic, anti-inflammatory, or
other therapies, their subsequent clinical scores are dropped from the analysis. Typically,
serum antibody titers of both vaccinated and control horses increase after challenge. EIV
vaccines must also be tested for sterility, purity, freedom from extraneous agents, batch
potency, and safety, i.e., absence of abnormal local or systemic reactions in the recipient
horse following vaccination. For inactivated-virus vaccines, potency standardization is
typically done by single radial diffusion assay [242].
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Table 5. Scoring system of clinical signs in horses infected with EIV during experimental challenge.
Clinical Sign Description Score
Coughing No cough during daily observation period 0
Coughing once during daily observation 1
Coughing twice or more during observation 2
Nasal discharge No discharge 0
Serous discharge 1
Mucopurulent discharge 2
Profuse mucopurulent discharge 3
Respiration Normal (<36/min) 0
Abnormal (dyspnea, tachypnea > 36/min) 1
Depression No depression 0
Depression present (lethargy, inappetence) 1
13. Vaccine Updating
As described elsewhere, EIV strains in circulation undergo antigenic drift, albeit at
a much slower rate than human, avian, or swine IAV. Therefore, vaccine manufacturers,
to keep up with antigenic drift, should periodically update the virus strains in their
vaccines. However, vaccine manufacturers are not required to do so, and it is possible
for a product to remain on the market long after it has become antigenically obsolete.
Leading manufacturers understand the scientific need for updating, but prior to the 1990s,
there was no guidance, as the evolution of EIV H3N8 HA at the molecular level was just
beginning to be understood. In the wake of large outbreaks of EIV in Europe in 1989 and
in Hong Kong in 1992, Dr. Jennifer A. Mumford (Animal Health Trust, Newmarket, UK)
instigated a series of meetings that for the first time brought together virologists from
around the world to address the problem [243]. Those meetings led to the realizations that
there were two cocirculating lineages of EIV H3N8 HA that had significantly diverged
from the vaccine virus strains in use (mainly Fontainebleau/79, Kentucky/81) [85], and
there had been no confirmed isolations of equine H7N7 virus since 1979 [81]. The meetings
further led in 1995 to the founding of the international OIE/World Health Organization
(WHO) Equine Influenza Expert Surveillance Panel (hereafter ESP). This consists of the
heads of the OIE’s international reference laboratories for EI, one or more representatives
of WHO Collaborating Centers for influenza, heads of national or regional EIV surveillance
operations (e.g., [94,244]), and veterinary virologists who actively study EI in regions
including South America and east Asia. The role of the ESP is to serve as an advisory
body to the equine industry regarding the updating of vaccine virus strains. Its members
collate information on regional EIV outbreaks, the virus strains responsible for them, and
vaccination status of affected horses. Member laboratories perform virus characterizations
including nucleotide sequencing and antigenic comparison using reference antisera, which
information feed into antigenic cartography analysis. On these bases, the panel, meeting
annually, debates whether the vaccine strains are still a good antigenic match for the
virus strains in current circulation and, if not, then what the updated vaccine strains
should be. The OIE publishes the ESP’s annual conclusions and recommendations in
its Bulletin (online at oiebulletin.com). Both the European Medicines Agency [245] and
the USDA [246] have EI vaccine updating guidelines that recognize the guidance of the
OIE–ESP recommendations.
The technique of antigenic cartography [247] has become a critical component of the
evaluation of antigenic drift in EIV isolates. This technique, involving multidimensional
correlation of masses of HI data comparing new vs. old virus strains against a panel of
reference ferret antisera, demonstrated the antigenic divergence of the H3N8 EIV into
the “Eurasian” lineage and the “American” FC-1 and FC-2 sublineages [248]. These each
form distinguishably separate antigenic clusters. The ESP has followed a policy that,
so long as new isolates continue to map to the existing FC-1 and FC-2 clusters, i.e., are
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antigenically indistinguishable from the clade prototype strains, the standing vaccine virus
strain recommendations for those clades remain prima facie valid. This has produced the
surprising outcome that, as late as 2021, the recommended vaccine virus strains remain
influenza A/equine/South Africa/2003-like virus (e.g., Ohio/03) for FC-1 and influenza
A/equine/Richmond/2007-like virus for FC-2. That is to say, 18 years of antigenic drift
has not yet caused the replacement of the FC-1 cluster in the actively circulating EIV, which
these authors would not have predicted. Recent large outbreaks in Europe and the UK in
2018–2019, which initially raised concerns about possible emergence of an antigenically
new variant, were instead the outcome of the reintroduction of FC-1 EIV into a region where
it had been long absent [14]. This was supported by comparative serum neutralization test
as well as by HI results [249]. It must be noted that current EIV antigenic cartography is
focused only upon HA, because HI data is its resource, and while in principle it could be
applied to NA, as well, there is no data for it to analyze. Sequence information shows that
EIV NA is also subject to antigenic drift and has established clades that mirror the FC-1
and FC-2 lineages of HA [80], but the significance for EI vaccines of antigenic drift in NA is
poorly understood. Serum neutralization testing using pseudotyped-EIV is one approach
to overcome this limitation [232,250]. Comparative serum binding to a purified EIV NA
protein antigen by enzyme-linked lectin assay (ELLA) [251]) is being investigated.
With regard to the equine H7N7 subtype, the ESP concluded in 1999 that it was no
longer relevant and should be dropped from EI vaccines. This has been done in most
current vaccines. Occasionally, there have arisen reports suggesting that this subtype
may still survive in equids (e.g., [252,253]), but the ESP has not obtained any virus isolate
in support of these claims. Part of the problem may be that, for EIV H7N7 serological
testing, nonspecific inhibitors of hemagglutination require more stringent removal (i.e.,
trypsin–periodate) to eliminate false-positive results, as discussed above [224]. Diagnostic
testing must still include testing for the EIV H7N7 on the chance, however unlikely, that
it may still survive in some hidden natural reservoir. Various strains of EIV H7N7 do
survive in storage in multiple laboratories. That leads to a final confounding factor, the
reappearance in the field of anachronistic H3N8 EIV strains, termed “frozen evolution”
(e.g., [86,254]). These strains, which usually resemble old vaccine strains, bear HA, whose
nucleotide sequence would phylogenetically date them as 5–20 years older than their date
of isolation. Thus, these are analogous to the reemergence of human H1N1 IAV in 1977.
Fortunately, the anachronistic EIV strains have never yet persisted. The presumption is
that these strains escaped from frozen storage.
This ESP system is fundamentally similar to the WHO system for updating of human
influenza vaccines. The important difference is scale: the WHO human influenza system
has probably 100-fold greater input of virus characterization data and at least 10-fold
greater geographical comprehensiveness. The WHO system operates on a tight schedule,
which it can do by taking advantage of the seasonality of “normal” human influenza, and
which it must do because an update of at least one vaccine strain is needed almost annually.
EI vaccine strain updates have been much less frequent, and so far, the existing ESP system
has been adequate in scale. Geographical coverage has improved since 1995 through its
association with OIE.
Swine and canine IAV are not analogous. In the US, swine do travel from one exhibi-
tion to another and carry swine influenza virus (SIV) with them (e.g., [255,256]); but swine
do not travel internationally, and therefore, swine influenza is not a listed disease in the OIE
Terrestrial Animal Health Code. There is a swine influenza branch of the OIE-FAO animal
influenza network (OFFLU), but neither it nor any other international body is tasked with
making vaccine strain recommendations; that is left to national-level organizations, and
there is a need for heightened SIV surveillance in much of the world [257]. The European
Union in 2001 instigated a series of SIV surveillance network programs (ESNIP, [258]),
that is largely industry-funded. Similarly to EI, swine influenza is not a notifiable disease
in the US, but the USDA established a SIV surveillance program through the National
Animal Health Laboratory Network in 2009 [257,259]. Swine population structures and
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management are much different than in equines, with many animals in close contact,
often continuously indoors, and a high rate of turnover ensuring a constant supply of
juvenile pigs as breeding grounds for porcine respiratory disease complex. Outbreaks are
more readily detected, and virological sampling is facilitated by the rope-chewing and
snout-wipe methods. Thus, SIV surveillance efforts can generate larger data inputs than
the ESP can obtain. SIV also presents a more complex problem than EIV: there are more
relevant IAV subtypes, gene constellations, and lineages in cocirculation; there are also
high probabilities of reassortment of SIV with human or avian IAV strains; and SIV has
zoonotic potential as a human pathogen.
Canines also seldom travel internationally, and CIV is also not a notifiable or trans-
boundary disease. As with SIV, there is no international panel that recommends vaccine
CIV strains. A surveillance network exists for CIV in the US, headed by the Animal Health
Diagnostic Center at Cornell University, New York. This network currently has 12 partners
among the veterinary diagnostic laboratories of different states that have collected >40,000
samples since 2015 with some-3000 positive test results [260].
14. Conclusions
EI is one of the most important respiratory diseases of horses. The economic burden
of this disease imposed on equine industry and equestrian events runs into billions of
dollars [261], and EI also exacts a considerable cost in developing nations where equids are
still widely used as working animals. As a result, reinforced efforts aimed at preventing
EI outbreaks in horse populations are valuable contributions to the continued survival of
large and small equine operations. Vaccination remains the most effective approach for
controlling harmful pathogenic viral infections, including EI. In this review, we discussed
how the unique biology of EIV facilitates the design of different kinds of vaccines and
reviewed data supporting their safety and efficacy in equine subjects, including the pros
and cons regarding each vaccine approach. The constant evolution of EIV, transboundary
nature of the disease, and evidence of poor vaccine performance have necessitated an
ongoing international surveillance effort, unique for animal influenza viruses, advising on
the updating of EIV strains incorporated in commercially marketed EI vaccines.
Challenges: Despite the availability of different types of vaccines against EI, there are
certain challenges to effective immunization in horses against EI identified in this review.
These include the constant evolution of the virus, vaccine breakdown, vaccination-induced
short-lived immunity, immunity gap, inability of vaccines to induce sterilizing immunity,
and, in young horses, interference with maternally derived immunity [110,114,115].
Future Directions: Many EI vaccine technologies are used or being investigated for
their safety and ability to induce long-lasting protective immunity. So far, it appears that
only MLV can induce a long-lasting protective immunity by triggering multiple arms of the
immune system. To mimic this, the use of viral proteins with immunodominant epitopes
for CD4+ and CD8+ T cell responses as immunogens in other vaccine systems, especially
recombinant DNA-based systems, may be beneficial. In addition, the advent of EI new vac-
cine technologies has facilitated the development of DIVA-capable vaccines. This enables
mass vaccination programs against EI without compromising the serological identification
of convalescent horses. Considerable practical experience with mRNA vaccines has been
gained from their use against SARS-CoV-2, and this technology may soon find veterinary
applications against pathogens such as EIV. Many groups are evaluating EI vaccines to
understand how to induce long-lasting sterilizing immunity, reduce the effect of strain
differences, and close the immunity gap between vaccine doses in young horses. As with
human influenza, the prospect of a universal EIV vaccine targeting conserved domains is
tantalizingly close.
Since neither EI vaccine coverage nor surveillance are universal, influenza in horses is
not going away in the foreseeable future. However, the results from these studies should
lead to more improved EI vaccines that will reduce the severity and spread of EI disease
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outbreaks into minor episodes and also help to combat newly emerging EIV strains in the
future.
Author Contributions: For research articles with several authors, the following statements should
be used “Conceptualization, F.S.O., L.M.-S. and T.M.C.; methodology, F.S.O. and L.M.-S.; software,
F.S.O. and S.O.O.; validation, L.M.-S. and T.M.C.; formal analysis, F.S.O. and S.O.O.; investigation,
F.S.O., S.O.O., L.M.-S. and T.M.C.; resources, F.S.O., S.O.O., L.M.-S. and T.M.C.; data curation, F.S.O.,
S.O.O., L.M.-S. and T.M.C.; writing—original draft preparation, F.S.O., S.O.O., L.M.-S. and T.M.C.;
writing—review and editing, F.S.O., S.O.O., L.M.-S. and T.M.C.; visualization, F.S.O., S.O.O., L.M.-S.
and T.M.C.; supervision, L.M.-S. and T.M.C.; project administration, L.M.-S. and T.M.C.; funding
acquisition, N/A. All authors have read and agreed to the published version of the manuscript.”
Funding: This research received no external funding.
Acknowledgments: TMC was supported by a project of the Kentucky Agricultural Experiment
Station (KY014053, National Institute of Food and Agriculture, U.S. Department of Agriculture,
Animal Health Program). Schematic representations in Figures 1, 3B and 5 were created using
Biorender (©Biorender—biorender.com).
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
AAEP American Association of Equine Practitioners
APC Antigen presenting cells
att Attenuated
BGH Bovine growth hormone
ca Cold-adapted
CIV Canine influenza virus
CMI Cell mediated immunity
CTL Cytotoxic T-lymphocytes
DIVA Differentiation of infected from vaccinated animals
EI Equine influenza
EID50 50% egg infective dose
EIV Equine influenza virus
ELLA Enzyme-linked lectin assay
ELISA Enzyme-linked immunosorbent
ESP Expert Surveillance Panel
FAO Food and agriculture organization
FC-1 Florida clade 1
FC-2 Florida clade 2
FEI Federation Equestre Internationale
HA Hemagglutinin
HI Hemagglutination inhibition
IAV Influenza A virus
IBV Influenza B virus
IFN Interferon
ISCOM Immunostimulating complexes
IFHA International Federation for Horseracing Authorities
LAIV Live attenuated influenza vaccine
MDCK Madin–Darby Canine Kidney
MDV Master donor virus
MHC Major histocompatibility complex
MLV Modified-live attenuated vaccines
M1 Matrix protein 1
M2 Matrix protein 2
NA Neuraminidase
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NAb Neutralizing antibodies
NEP Nuclear export protein
NCR Noncoding regions
NP Nucleoprotein
NS1 Nonstructural protein 1
OIE Office International des Epizooties
PA Polymerase acidic protein
PB1 Polymerase basic protein 1
PB2 Polymerase basic protein 2
PBMC Peripheral blood mononuclear cells
RDE Receptor-destroying-enzyme
SIV Swine influenza virus
SRH Single radial hemolysis
ts Temperature sensitive
URT Upper respiratory tract
USDA US Department of Agriculture
WHO World Health Organization
WT Wild type
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